
Oncology
2024-11-27

Overexpression of the human epidermal growth factor receptor 2 (HER2) is increasingly recognized as a common molecular abnormality in gastric and gastroesophageal cancer. Drugs targeting the HER2 protein have shown promise in treating these cancers. Additionally, there is evidence to suggest that DS-8201a, a HER2-targeted antibody-drug conjugate (ADC), may be effective and safe in treating patients with heterogeneous or low HER2 expression. To aid in the design of personalized or precision drug treatment strategies for HER2-targeted therapies in clinical trials, GemPharmatech offers suitable patient-derived xenograft (PDX) gastric cancer models.
More infomation about blogs

Let us know which event you're attending and we'd be happy to connect with you.